Late relapse in patients with diffuse large B-cell lymphoma.

Area of Science:

• Hematology
• Oncology
• Clinical Medicine

Background:

• Diffuse large B-cell lymphoma (DLBCL) is an aggressive non-Hodgkin lymphoma.
• Treatment with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP)-like regimens can achieve complete remission.
• Relapse after initial remission is a significant challenge in DLBCL management.

Purpose of the Study:

• To compare outcomes of patients with DLBCL experiencing late relapse (≥5 years post-remission) versus early relapse (<5 years post-remission).
• To identify prognostic factors influencing survival after relapse in DLBCL patients.

Main Methods:

• Retrospective analysis of 162 DLBCL patients treated with CHOP-like regimens who achieved complete remission.
• Categorization into early relapse (<5 years) and late relapse (≥5 years) groups.
• Comparison of prognostic characteristics at diagnosis and survival post-relapse using statistical analyses, including multivariate analysis.

Main Results:

• Late relapsing patients presented with more favorable prognostic factors at diagnosis (e.g., lower stage, normal LDH, better performance score).
• Three-year survival post-relapse was better for late relapsers (48% vs. 25%), but 5- and 10-year survival rates were similar between groups.
• Multivariate analysis identified age and B-symptoms as predictors of survival, whereas relapse timing (early vs. late) was not significant.

Conclusions:

• While late relapse in DLBCL may be associated with better initial prognostic indicators and short-term survival advantage, overall long-term survival post-relapse is comparable to early relapsers.
• Age and presence of B-symptoms are critical factors for predicting survival outcomes after relapse in DLBCL.
• A small subset of late relapsing patients may achieve prolonged second remissions, but most patients eventually succumb to the disease.